Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

714
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
714
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

160
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
160
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Medical Biochemistry And Metabolomics
  9. Medical Biochemistry - Proteins And Peptides (incl. Medical Proteomics)
  11. The Effect On Quality Of Life Of Therapeutic Plasmapheresis And Intravenous Immunoglobulins On A Population Of Myalgic Encephalomyelitis/chronic Fatigue Syndrome Patients With Elevated Β-adrenergic And M3-muscarinic Receptor Antibodies-a Pilot Study

The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies-A Pilot Study

Boglárka Oesch-Régeni1,2, Nicolas Germann3, Georg Hafer4

  • 1Division of Nephrology and Transplant Medicine, HOCH Health Eastern Switzerland, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland.

Journal of Clinical Medicine
|June 13, 2025

Related Experiment Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.3K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

11.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

View abstract on PubMed

Summary
This summary is machine-generated.

This pilot study found that higher autoantibody levels in ME/CFS patients are linked to poorer quality of life. Antibody-lowering treatments show potential for improving well-being in myalgic encephalomyelitis/chronic fatigue syndrome.

Area of Science:

  • Immunology
  • Neurology
  • Pathology

Background:

  • Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex condition with suspected immune system involvement and potential autoimmunity.
  • A subset of post-COVID-19 condition (PCC) patients meet ME/CFS diagnostic criteria, suggesting infectious triggers like SARS-CoV-2.
  • ME/CFS diagnosis involves specific symptoms including fatigue, post-exertional malaise, sleep issues, pain, and neurological/cognitive problems, alongside autonomic, neuroendocrine, or immune manifestations.

Purpose of the Study:

  • To identify ME/CFS patients among long COVID individuals exhibiting elevated autoantibodies.
  • To investigate the association between specific autoantibody concentrations and clinical outcomes in ME/CFS patients.
  • To assess the feasibility and potential therapeutic effects of antibody-lowering treatments like plasmapheresis and IVIGs.
Keywords:
EQ-5D-5LG protein-coupled receptorsIVIGM3-muscarinic acetylcholine receptor antibody

Related Experiment Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.3K
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

11.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K

Main Methods:

  • Seven ME/CFS patients with elevated autoantibodies underwent plasmapheresis (PE) and intravenous immunoglobulins (IVIGs).
  • Autoantibody levels were measured before the first PE and two weeks post-final PE.
  • Clinical outcomes were monitored using the Schellong test, ISI, FSS, HADS, and EQ-5D-5L questionnaires at various time points.

Main Results:

  • A negative association was observed between β2-adrenergic and M3-muscarinic receptor autoantibody concentrations and quality of life (EQ-5D-5L scores).
  • Increased autoantibody levels correlated with decreased quality of life scores.
  • No significant associations were found between β1-adrenergic and M4-muscarinic receptor antibodies and fatigue, insomnia, depression, or anxiety scores.

Conclusions:

  • This pilot study suggests a link between elevated autoantibody levels and reduced somatic and psychological well-being in selected ME/CFS patients.
  • The findings indicate potential therapeutic benefits of antibody-lowering strategies for ME/CFS.
  • Further research with larger sample sizes is required to validate these preliminary results and explore the therapeutic potential of antibody-reduction methods.
M4-muscarinic acetylcholine receptor antibody
ME/CFS
adrenergic β1-receptor antibody
adrenergic β2-receptor antibody
long COVID
microclots
plasmapheresis
post-COVID-19 condition (PCC)
postacute sequelae of SARS-CoV-2 infection (PASC)
psychometry
quality of life